N-(2-Chloro-6-Methylphenyl)-2-((6-Chloro-2-Methyl-4-Pyrimidinyl)Amino)-5-Thiazolecarboxamide

Chemical Identity and Analytical Fingerprint

The compound N-(2-Chloro-6-Methylphenyl)-2-((6-Chloro-2-Methyl-4-Pyrimidinyl)Amino)-5-Thiazolecarboxamide, registered under CAS 302964-24-5, carries the molecular formula C₁₆H₁₃Cl₂N₅OS and a monoisotopic mass of 393.0218 Da. Its structure integrates a 2-chloro-6-methylphenyl carboxamide terminus linked through a 2-aminothiazole-5-carboxamide bridge to a 6-chloro-2-methylpyrimidin-4-yl pharmacophore, a scaffold critical to its role as a late-stage intermediate in tyrosine kinase inhibitor synthesis. High-performance liquid chromatography with UV detection at 254 nm (area% method, C18 column, acetonitrile/0.1% TFA gradient) typically resolves the target peak at a retention time relative to the Dasatinib API of approximately 0.85. Infrared spectroscopy confirms diagnostic bands: sharp amide C=O stretch at 1668 cm⁻¹, secondary amine N–H bending near 1535 cm⁻¹, and aromatic C–Cl modes between 750–690 cm⁻¹. Identity can be unambiguously verified by ¹H NMR (DMSO-d₆, 400 MHz): the thiazole C5-H singlet appears at 8.28 ppm, the pyrimidine C5-H singlet at 6.92 ppm, and the 2-chloro-6-methylphenyl methyl protons resonate as a sharp singlet at 2.28 ppm.

Specifications and Lot-Release Criteria

Commercial material intended for cGMP intermediate supply chains is routinely released against the metrics in Table 1. The primary assay method employs reversed-phase HPLC with external standard calibration against a qualified reference batch, with system suitability demanding resolution ≥ 2.0 between the target peak and the de-chloro impurity (6-hydroxy analog). Water content by Karl Fischer coulometry (USP <921>, Method Ic) must remain below 0.5% w/w prior to packaging because residual moisture accelerates hydrolysis of the pyrimidinyl chloride moiety, generating the inactive hydroxy degradant that co-elutes with the API in non-orthogonal HPLC systems. Heavy metals screening (USP <231> or Ph. Eur. 2.4.8) targets ≤ 20 ppm for total heavy metals, with a specific limit of ≤ 2 ppm for palladium derived from Suzuki or Buchwald–Hartwig steps upstream.

The compound crystallizes as an off-white to pale-yellow powder with a melting endotherm onset near 242–246 °C (DSC, 10 K/min, nitrogen) and a polymorphic profile monitored by XRPD. Batches exhibiting an additional endotherm below 200 °C are rejected because this indicates residual solvate formation that compromises downstream coupling yield. Storage in amber glass under argon at –20 °C limits hydrolytic and photolytic degradation; accelerated stability data at 40 °C/75% RH (ICH Q1A conditions) show 0.8–1.2% assay loss over 6 months when packaged with a desiccant sachet.

The only practical difference between this intermediate and the 6-(4-(2-hydroxyethyl)piperazin-1-yl) derivative (the immediate precursor to Dasatinib) lies in the halogen substitution on the pyrimidine ring. The chloro substituent serves as the electrophilic handle for the final nucleophilic aromatic substitution (SNAr) with 2-(piperazin-1-yl)ethanol, typically run in DMAc at 80–85 °C in the presence of DIPEA. Competition from hydrolysis of the 6-chloro group necessitates scrupulous drying of reagents; water content in DMAc must be verified by KF to ≤ 0.01% to restrict the hydroxy-impurity formation to below 0.10% in the crude product. Production-scale campaigns running on 500–1000 L vessels frequently install an inline NIR probe to track the disappearance of the C–Cl band at 740 cm⁻¹, terminating the reaction when residual starting material drops below 0.5% area by HPLC.

What Limits the Purity Profile of Chloro-Pyrimidinyl Intermediates?

Process-related impurities in N-(2-Chloro-6-Methylphenyl)-2-((6-Chloro-2-Methyl-4-Pyrimidinyl)Amino)-5-Thiazolecarboxamide fall into three orthogonal categories: regioisomeric thiazole coupling products, over-chlorinated dimers, and solvolytic degradants. Mass spectrometric tracking (LC-QTOF, ESI+ mode) on pilot-plant batches identifies the 2-chloro-6-methylaniline-derived urea byproduct as the primary high-molecular-weight contaminant when the amidation step is pushed above 85 °C, requiring a cross-flow nanofiltration step (MWCO 400 Da) to meet the ≤ 0.10% unspecified impurity threshold. The regioisomeric risk originates from the HATU-mediated coupling of 2-amino-5-thiazolecarboxylic acid with the aniline: acylation at the less-hindered thiazole N3 position is thermodynamically disfavored but can reach 2–3% of the product mixture if the temperature falls below 0 °C due to kinetic trapping. Reactor control on a 200 L Hastelloy vessel must therefore maintain an isothermal jacket setpoint of 5 ± 1 °C during the first 30 min of addition.

Differences from alternative Dasatinib penultimate intermediates such as the 6-bromo analog (CAS 302964-25-6) or the 6-iodo analog are most pronounced in SNAr reactivity and genotoxic impurity control. The 6-chloro derivative offers a balanced reactivity profile: while the bromide reacts roughly 1.8× faster with N-methylpiperazine, it generates a borderline purge factor for the genotoxic bromo impurity (ICH M7 Class 3), pushing the acceptable daily intake calculation to below 150 µg/day and necessitating multi-step recrystallization. The chloride, by contrast, permits straightforward purge to 0.05% carry-through by a single ethanol/water slurry at 60 °C. The 6-iodo analog, though even more reactive, introduces heavy-atom quenching that reduces fluorescence detection sensitivity during IPC, complicating real-time reaction monitoring in GMP suites. Consequently, the chloro intermediate has become the default specification in all ANDA filings referencing Sprycel® since 2018, despite the marginally longer reaction time (12–14 h versus 8–9 h for the bromide).

2.5 wt% moisture activated-carbon treatment (Darco G-60), after dissolution in THF at 45 °C and polish-filtration through a 0.45 µm PTFE membrane, reduces palladium from 12–18 ppm to consistently below 2 ppm while removing color bodies that would otherwise quench the fluorescence of the final API. This unit operation is incompatible with the 6-bromo analog because partial debromination occurs under the same mildly acidic pH conditions, generating the des-halo impurity that co-elutes during preparative HPLC. The structural specificity of this purification sequence underscores why the chloro intermediate is preferred over higher-halogen congeners in multi-ton campaigns governed by ICH Q7.